TESAMORELIN

Description

Tesamorelin is a synthetic peptide analogue of GHRH with a trans-3-hexenoic acid moiety anchored at the N-terminus of its 44-amino acid sequence, providing enhanced stability compared to endogenous GHRH. The compound stimulates pituitary secretion of growth hormone and subsequently increases insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels in laboratory models.

Properties of Tesamorelin

Peptide Sequence:Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Chemical Formula: C223H370N72O69S
Molecular Mass: 5196 g/mol
CAS Number: 901758-09-6
PubChem: 44147413
Vial Size: 3ml

Peptide Sequence:

Lyophilized Peptides:

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.

This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.

Tesamorelin is a stabilized GHRH analogue that exhibits regulatory effects on metabolism through its influence on the growth hormone/IGF-1 axis. In research models, the compound demonstrates the capacity to affect visceral adipose tissue metabolism, triglyceride levels, and lipid profiles through combined anabolic and lipolytic mechanisms without significant impact on glucose homeostasis in controlled settings.

Efficacy in Reducing Visceral Adipose Tissue

Tesamorelin has been shown to effectively reduce visceral adipose tissue (VAT) in people with HIV-associated lipodystrophy. In two well-designed trials, tesamorelin significantly decreased VAT without affecting subcutaneous adipose tissue to a clinically significant extent. This reduction was maintained over a longer term in patients who continued therapy, although VAT reaccumulated upon discontinuation1.

Additionally, tesamorelin improved body composition measures such as trunk fat and waist circumference, and enhanced body image parameters1.

Impact on Non-Alcoholic Fatty Liver Disease (NAFLD)

Tesamorelin has demonstrated promising results in reducing liver fat and preventing fibrosis progression in HIV-associated NAFLD. A randomized placebo-controlled trial showed that tesamorelin reduced hepatic fat fraction and improved fibrosis-related gene scores, indicating a potential therapeutic role in managing NAFLD in this population2.

The peptide modulated hepatic gene pathways, increasing oxidative phosphorylation and decreasing inflammation-related gene expressions2.

Effects on Fat Quality

Beyond reducing fat quantity, tesamorelin has been found to improve fat quality. In trials assessing fat density, tesamorelin increased both VAT and subcutaneous adipose tissue density, suggesting an enhancement in fat quality independent of quantity changes3.

Cardiovascular and Metabolic Outcomes

Tesamorelin’s impact on cardiovascular disease (CVD) risk has been explored, with findings indicating a modest reduction in 10-year atherosclerotic CVD risk scores. This reduction was primarily driven by decreases in total cholesterol, even among participants on lipid-lowering therapies4.

Furthermore, tesamorelin was well-tolerated, with no significant differences in glucose parameters observed between treatment and placebo groups1.

Neurocognitive and Other Health Implications

While tesamorelin reduced waist circumference, its effects on neurocognitive impairment in abdominally obese subjects with HIV were not significantly different from standard care, suggesting limited cognitive effects5.

However, the peptide’s ability to increase insulin-like growth factor 1 (IGF-1) levels may have other experimental research applications worth exploring further5.

References

Falutz, J., Mamputu, J., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. The Journal of clinical endocrinology and metabolism, 95 9, 4291-304 . https://doi.org/10.1210/jc.2010-0490.
Fourman, L., Billingsley, J., Agyapong, G., Sui, S., Feldpausch, M., Purdy, J., Zheng, I., Pan, C., Corey, K., Torriani, M., Kleiner, D., Hadigan, C., Stanley, T., Chung, R., & Grinspoon, S. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5. https://doi.org/10.1172/jci.insight.140134.
Lake, J., La, K., Erlandson, K., Adrian, S., Yenokyan, G., Scherzinger, A., Dubé, M., Stanley, T., Grinspoon, S., Falutz, J., Mamputu, J., Marsolais, C., McComsey, G., & Brown, T. (2021). Tesamorelin improves fat quality independent of changes in fat quantity. AIDS, 35, 1395 – 1402. https://doi.org/10.1097/QAD.0000000000002897.
Grinspoon, S., Fourman, L., Stanley, T., McGary, C., Benkeser, D., & Cash, R. (2025). P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis. Open Forum Infectious Diseases, 12. https://doi.org/10.1093/ofid/ofae631.633.
Ellis, R., Vaida, F., Hu, K., Dube, M., Henry, B., Chow, F., Heaton, R., Lee, D., & Sattler, F. (2025). Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.. The Journal of infectious diseases. https://doi.org/10.1093/infdis/jiaf012.